[Skip to Navigation]
Sign In
Correction
September 2021

Error in Abstract

JAMA Oncol. 2021;7(9):1406. doi:10.1001/jamaoncol.2021.4035

In the Original Investigation titled “Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer,”1 published online July 8, 2021, there was an error in the Results section of the Abstract. The median (interquartile range) overall survival and time on treatment was 43 (16.2-unavailable) and 14 (6.0-26.22) months, respectively, among the cohort of patients who received pertuzumab, rather than the entire population. This article has been corrected online.

References
1.
Ethier  J-L, Desautels  D, Robinson  A, Amir  E, Kong  W, Booth  CM.  Practice patterns and outcomes of novel targeted agents for the treatment of ERBB2-positive metastatic breast cancer.   JAMA Oncol. Published online July 8, 2021. doi:10.1001/jamaoncol.2021.2140PubMedGoogle Scholar
×